CN103874512B - 选择性递送分子及使用方法 - Google Patents

选择性递送分子及使用方法 Download PDF

Info

Publication number
CN103874512B
CN103874512B CN201280047936.9A CN201280047936A CN103874512B CN 103874512 B CN103874512 B CN 103874512B CN 201280047936 A CN201280047936 A CN 201280047936A CN 103874512 B CN103874512 B CN 103874512B
Authority
CN
China
Prior art keywords
seq
amino acid
molecule
amino acids
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280047936.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103874512A (zh
Inventor
刘俊杰
吉瑟斯·冈萨雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avelas Biosciences Inc
Original Assignee
Avelas Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avelas Biosciences Inc filed Critical Avelas Biosciences Inc
Publication of CN103874512A publication Critical patent/CN103874512A/zh
Application granted granted Critical
Publication of CN103874512B publication Critical patent/CN103874512B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6432—Quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
CN201280047936.9A 2011-07-29 2012-07-27 选择性递送分子及使用方法 Expired - Fee Related CN103874512B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513287P 2011-07-29 2011-07-29
US61/513,287 2011-07-29
PCT/US2012/048732 WO2013019681A2 (en) 2011-07-29 2012-07-27 Selective delivery molecules and methods of use

Publications (2)

Publication Number Publication Date
CN103874512A CN103874512A (zh) 2014-06-18
CN103874512B true CN103874512B (zh) 2016-11-16

Family

ID=47629864

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280047936.9A Expired - Fee Related CN103874512B (zh) 2011-07-29 2012-07-27 选择性递送分子及使用方法

Country Status (12)

Country Link
US (6) US9278144B2 (enExample)
EP (2) EP3473273A1 (enExample)
JP (1) JP6124150B2 (enExample)
KR (1) KR102004558B1 (enExample)
CN (1) CN103874512B (enExample)
AU (1) AU2012290318B2 (enExample)
CA (1) CA2841249C (enExample)
DK (1) DK2736533T3 (enExample)
EA (1) EA030795B1 (enExample)
ES (1) ES2683377T3 (enExample)
MX (1) MX350082B (enExample)
WO (1) WO2013019681A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
CA2754072C (en) 2009-03-02 2019-01-15 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
JP2012533560A (ja) 2009-07-15 2012-12-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞における取り込みが制御可能なペプチド
MX350082B (es) 2011-07-29 2017-08-24 Avelas Biosciences Inc Moleculas de entrega selectiva y metodos de uso.
WO2014120837A2 (en) * 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
MX366375B (es) * 2013-01-30 2019-07-05 Avelas Biosciences Inc Moleculas de administracion selectiva y metodos de uso.
EP2988786A4 (en) * 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE
PL405046A1 (pl) * 2013-08-12 2015-02-16 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Pan Genetycznie kodowany oparty na FRET biosensor aktywności MMP-9 i jego zastosowanie
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
TW201809013A (zh) * 2016-06-06 2018-03-16 艾斯克立必恩股份有限公司 用於藥物遞送之抗體融合蛋白
CN110741242B (zh) * 2017-04-07 2023-07-07 艾维拉斯生物科学公司 比率荧光成像方法
US11192139B2 (en) 2017-06-22 2021-12-07 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
EP3642383B1 (en) 2017-06-22 2022-12-21 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
CN108096255B (zh) * 2017-12-28 2019-11-12 北京大学 地夫可特用于抑制或治疗胰腺癌的用途
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
WO2019204363A2 (en) * 2018-04-16 2019-10-24 Avelas Biosciences, Inc. Selective delivery of therapeutic and imaging agents
WO2020068920A2 (en) 2018-09-25 2020-04-02 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
CN110075322B (zh) * 2019-05-20 2021-07-06 复旦大学附属妇产科医院 一种靶向GnRH受体的近红外荧光成像探针及其制备方法与应用
US20220378780A1 (en) * 2019-09-23 2022-12-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising poh derivatives
WO2024233344A1 (en) * 2023-05-05 2024-11-14 The United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating tendon and bone injuries

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011008992A2 (en) * 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507389A (en) 1982-12-16 1985-03-26 Monsanto Company Determination of collagenase by reacting with peptide substrates
US4466919A (en) 1982-12-16 1984-08-21 Monsanto Company Peptide substrates for mammalian collagenase
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
DE69434810T2 (de) * 1993-11-16 2007-08-02 Bracco International B.V. Immobilisiertes markierungsverfahren
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6348185B1 (en) 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020009786A1 (en) 2000-04-18 2002-01-24 Tang Y. Tom Novel nucleic acids and polypeptides
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
WO2005019247A2 (en) 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
BRPI0507159A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
EP2322920B1 (en) * 2005-06-07 2014-12-10 Centre National de la Recherche Scientifique (CNRS) MALDI tissue imaging using conjugates cleavable by fast fragmentation
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
TW201004647A (en) 2008-05-20 2010-02-01 Sigma Tau Ind Farmaceuti Novel dual targeting antitumoural conjugates
WO2010014236A2 (en) * 2008-07-30 2010-02-04 The University Of North Carolina At Chapel Hill Acylhydrazone-based cleavable linkers
CN102159189B (zh) 2008-09-23 2013-06-12 加利福尼亚大学董事会 用于药物递送的纳米载体
BRPI0919403A2 (pt) 2008-09-26 2017-09-26 Ambrx Inc polipeptídeos modificados de eritropoetina animal e seus usos
KR101095841B1 (ko) 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도
BRPI1009346A2 (pt) 2009-03-19 2017-05-30 General Eletric Company metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit
WO2010121023A2 (en) 2009-04-15 2010-10-21 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
EP2523600A4 (en) * 2010-01-12 2015-07-15 Univ Ben Gurion TARGETED RELEASE SYSTEMS FOR DIAGNOSTIC APPLICATIONS
JP5580625B2 (ja) 2010-03-03 2014-08-27 住友化学株式会社 メタンスルホン酸アルキルエステル溶液の製造方法
US20120055055A1 (en) 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
ES2708662T3 (es) 2011-02-10 2019-04-10 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Péptidos hidrofóbicos modificados para el diagnóstico hepático específico
MX350082B (es) 2011-07-29 2017-08-24 Avelas Biosciences Inc Moleculas de entrega selectiva y metodos de uso.
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
MX366375B (es) 2013-01-30 2019-07-05 Avelas Biosciences Inc Moleculas de administracion selectiva y metodos de uso.
EP2988786A4 (en) 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011008992A2 (en) * 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable

Also Published As

Publication number Publication date
US20170044214A1 (en) 2017-02-16
WO2013019681A2 (en) 2013-02-07
US20190119327A1 (en) 2019-04-25
WO2013019681A3 (en) 2013-07-11
US9371367B1 (en) 2016-06-21
US20180057536A1 (en) 2018-03-01
EA201490385A1 (ru) 2014-07-30
KR102004558B1 (ko) 2019-07-26
AU2012290318B2 (en) 2016-09-01
US9504763B2 (en) 2016-11-29
HK1197184A1 (en) 2015-01-09
EP2736533A4 (en) 2015-03-04
EP3473273A1 (en) 2019-04-24
US20160220707A1 (en) 2016-08-04
US9840537B2 (en) 2017-12-12
US20150031852A1 (en) 2015-01-29
US9278144B2 (en) 2016-03-08
JP2014521661A (ja) 2014-08-28
EA030795B1 (ru) 2018-09-28
EP2736533A2 (en) 2014-06-04
EP2736533B1 (en) 2018-07-04
US20160152670A1 (en) 2016-06-02
DK2736533T3 (en) 2018-08-06
MX350082B (es) 2017-08-24
US10239919B2 (en) 2019-03-26
AU2012290318A1 (en) 2014-01-23
US10570178B2 (en) 2020-02-25
CA2841249A1 (en) 2013-02-07
CA2841249C (en) 2023-09-26
KR20140063587A (ko) 2014-05-27
JP6124150B2 (ja) 2017-05-10
ES2683377T3 (es) 2018-09-26
CN103874512A (zh) 2014-06-18
MX2014001138A (es) 2014-07-22

Similar Documents

Publication Publication Date Title
CN103874512B (zh) 选择性递送分子及使用方法
US20200376013A1 (en) Selective drug delivery compositions and methods of use
US10363313B2 (en) PSMA ligands and uses thereof
US20220001011A1 (en) Photodynamic therapy composition
US20220347306A1 (en) Selective delivery of therapeutic and imaging agents
KR20240066128A (ko) 암의 검출 및 치료를 위한 방법 및 제제
WO2019204364A1 (en) Compositions and methods for the selective delivery of therapeutic and imaging agents
HK1197184B (en) Selective delivery molecules and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161116

CF01 Termination of patent right due to non-payment of annual fee